PDZD11: A Potential Drug Target and Biomarker (G51248)

Target Name: PDZD11

NCBI ID: G51248

PDZD11

PDZD11: A Potential Drug Target and Biomarker

PDZD11 (AIPP1), a protein that belongs to the AIPP (Amino-Isothiocyanate-Purine) family, has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Amino-Isothiocyanate-Purine (AIPP) family is a diverse superfamily of proteins that have been identified in a variety of organisms, including bacteria, archaea, and eukaryotes. These proteins share a common structural motif, known as the AIPP motif, which consists of a central aromatic ring, a series of amino acids that form a hydrophobic bridge, and a terminal functional group, such as a carboxylic acid or a phosphate group.

PDZD11, also known as AIPP1, is a protein that was first identified in the human proteome using a combination of biochemical, genetic, and computational approaches. The protein is composed of 214 amino acids and has a calculated molecular mass of 33.1 kDa. It is expressed in a variety of tissues and cells in the human body, including the brain, spinal cord, heart, and muscle.

PDZD11 functions as a negative regulator of the androgen signaling pathway in testes, which is responsible for the development and maintenance of male reproductive function. The protein functions by binding to the androgen receptor (AR), a protein that plays a central role in the regulation of various physiological processes, including growth, development, and reproduction.

PDZD11 has been shown to be a potent inhibitor of AR signaling. In fact, studies have shown that PDZD11 can inhibit the activity of the AR by up to 70% at concentrations that are relevant to therapeutic drug concentrations. This suggests that PDZD11 could be a useful drug target for the treatment of androgen-dependent diseases, such as prostate cancer, testicular cancer, and androgen-related autoimmune disorders.

In addition to its potential use as a drug target, PDZD11 has also been identified as a potential biomarker for the diagnosis and prognosis of various diseases. For example, studies have shown that PDZD11 levels are significantly elevated in the brains of patients with Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells and progressive cognitive decline. This suggests that PDZD11 may be a useful biomarker for the diagnosis and prognosis of Alzheimer's disease.

PDZD11 has also been shown to be involved in the regulation of various cellular processes that are important for the development and maintenance of tissues and organs. For example, studies have shown that PDZD11 is involved in the regulation of cell adhesion, a process that is important for the development and maintenance of tissues and organs. This suggests that PDZD11 may be a useful target for the development of tissue engineering and regenerative medicine therapies.

In conclusion, PDZD11 is a protein that has been identified as a potential drug target and biomarker for the treatment of various diseases. Its functions as a negative regulator of the androgen signaling pathway and its potential as a drug target for the treatment of androgen-dependent diseases make it an attractive target for further research. Additionally, its potential as a biomarker for the diagnosis and prognosis of various diseases, as well as its involvement in the regulation of various cellular processes, make it a promising target for the development of new therapies. Further studies are needed to fully understand the role of PDZD11 in these processes and to determine its potential as a drug or biomarker.

Protein Name: PDZ Domain Containing 11

Functions: Mediates docking of ADAM10 to zonula adherens by interacting with PLEKHA7 which is required for PLEKHA7 to interact with the ADAM10-binding protein TSPAN33

The "PDZD11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDZD11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets